MX2024000757A - Variantes recombinantes de proteínas r-espondina y uso de las mismas. - Google Patents

Variantes recombinantes de proteínas r-espondina y uso de las mismas.

Info

Publication number
MX2024000757A
MX2024000757A MX2024000757A MX2024000757A MX2024000757A MX 2024000757 A MX2024000757 A MX 2024000757A MX 2024000757 A MX2024000757 A MX 2024000757A MX 2024000757 A MX2024000757 A MX 2024000757A MX 2024000757 A MX2024000757 A MX 2024000757A
Authority
MX
Mexico
Prior art keywords
proteins
espondin
recombinant variants
recombinant
variants
Prior art date
Application number
MX2024000757A
Other languages
English (en)
Spanish (es)
Inventor
Patrick Collombat
Paolo Botti
Original Assignee
Diogenx
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diogenx filed Critical Diogenx
Publication of MX2024000757A publication Critical patent/MX2024000757A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2024000757A 2021-07-15 2022-07-15 Variantes recombinantes de proteínas r-espondina y uso de las mismas. MX2024000757A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21305993 2021-07-15
EP22305328 2022-03-18
PCT/EP2022/069925 WO2023285686A2 (en) 2021-07-15 2022-07-15 Recombinant variants of r-spondin proteins and their use

Publications (1)

Publication Number Publication Date
MX2024000757A true MX2024000757A (es) 2024-04-18

Family

ID=82799950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024000757A MX2024000757A (es) 2021-07-15 2022-07-15 Variantes recombinantes de proteínas r-espondina y uso de las mismas.

Country Status (9)

Country Link
US (2) US20240383952A1 (https=)
EP (1) EP4370535A2 (https=)
JP (1) JP2024526356A (https=)
KR (1) KR20240040088A (https=)
AU (1) AU2022311529A1 (https=)
CA (1) CA3225626A1 (https=)
IL (1) IL310154A (https=)
MX (1) MX2024000757A (https=)
WO (1) WO2023285686A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230241161A1 (en) * 2020-01-10 2023-08-03 Inserm (Institutnationaldelasanteetdelarecherchemedicale) Rspo1 proteins and their use
CN120813594A (zh) * 2023-01-19 2025-10-17 迪奥根克斯公司 R-spondin蛋白的重组变体及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US8377653B2 (en) 2005-02-11 2013-02-19 Icosagen Cell Factory Oü Viral expression plasmids for production of proteins, antibodies, enzymes, virus-like particles and for use in cell-based assays
US7790446B2 (en) 2005-02-11 2010-09-07 Kosagen Cell Factory Oü Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products
AU2013204484B2 (en) * 2011-07-15 2016-05-12 Oncomed Pharmaceuticals, Inc. RSPO binding agents and uses thereof
WO2013049375A2 (en) * 2011-09-28 2013-04-04 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating beta cell proliferation
US9783784B2 (en) * 2013-01-04 2017-10-10 City Of Hope Methods for establishing and improving the survival of a population of pancreatic progenitor or stem cells
US9777052B2 (en) * 2014-12-02 2017-10-03 The Board Of Regents Of The University Of Oklahoma R-spondin variants, compositions, and methods of use
WO2018140821A1 (en) * 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
JP2021020900A (ja) * 2019-07-29 2021-02-18 国立大学法人北海道大学 糖代謝異常改善剤

Also Published As

Publication number Publication date
KR20240040088A (ko) 2024-03-27
WO2023285686A3 (en) 2023-03-02
EP4370535A2 (en) 2024-05-22
CA3225626A1 (en) 2023-01-19
US20230340044A1 (en) 2023-10-26
JP2024526356A (ja) 2024-07-17
IL310154A (en) 2024-03-01
US20240383952A1 (en) 2024-11-21
WO2023285686A2 (en) 2023-01-19
AU2022311529A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
CO2019006917A2 (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
UY34859A (es) Análogos peptídicos de la exendina 4.
CO2018004758A2 (es) Composiciones oligonucleotídicas y sus métodos
UY36779A (es) Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
BR112019011144A2 (pt) compostos como agonistas peptídicos de receptor de glp1/glucagon/gip
GT201400166A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca
AR092925A1 (es) Derivados de exendina-4 como agonistas duales de glp1 / glucagon
ECSP14030742A (es) Proteínas del factor 21 de crecimiento del fibroblasto
MX2019001633A (es) Proteina derivada de la seda para el tratamiento de la inflamacion.
CO2022003156A2 (es) Inmunocitoquina que comprende un complejo de proteína heterodimérico basado en il-15/il-15rα y su uso
BR112014026057A2 (pt) análogos limitados por anel como inibidores de arginase
MX2021014789A (es) Vectores aav con el promotor de la proteina cero de mielina y usos de los mismos para el tratamiento de enfermedades asociadas a las celulas de schwann como la enfermedad de charcot-marie-tooth.
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
GT201700224A (es) Proteína de unión a rgma y su uso
MX2024000757A (es) Variantes recombinantes de proteínas r-espondina y uso de las mismas.
CO2023005057A2 (es) Compuestos y composiciones como moduladores de señalización tlr
AR083126A1 (es) Composicion vacunal para el control de las infestaciones por ectoparasitos
PE20130379A1 (es) Metodos para el tratamiento de las ulceras del pie diabetico
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
MX390157B (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
CO6592047A2 (es) Formulación tópica oftálmica de péptidos
MX2019000235A (es) Eliminacion de la cistina mediada por enzimas humanas.
MX2024006801A (es) Polipeptidos quimericos de adiponectina, vesicula extracelular que los comprende y usos de los mismos.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.